Mesoblast (NASDAQ:MESO) Stock Rating Upgraded by Cantor Fitzgerald

Mesoblast (NASDAQ:MESO) was upgraded by investment analysts at Cantor Fitzgerald to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Piper Sandler restated an “overweight” rating and issued a $24.00 price target (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Mesoblast has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Mesoblast Trading Up 0.7 %

Mesoblast stock opened at $14.82 on Tuesday. Mesoblast has a 12 month low of $2.00 and a 12 month high of $22.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The stock has a fifty day simple moving average of $17.99 and a two-hundred day simple moving average of $12.31.

Hedge Funds Weigh In On Mesoblast

Several institutional investors and hedge funds have recently bought and sold shares of MESO. R Squared Ltd purchased a new position in Mesoblast during the fourth quarter valued at $30,000. Barclays PLC purchased a new position in Mesoblast during the fourth quarter valued at $38,000. Lindbrook Capital LLC lifted its position in Mesoblast by 70.9% during the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after purchasing an additional 901 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Mesoblast during the fourth quarter valued at about $50,000. Finally, BNP Paribas Financial Markets raised its holdings in Mesoblast by 86,566.7% during the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock valued at $51,000 after acquiring an additional 2,597 shares during the period. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.